Patents have become a cornerstone of the biotech industry, and many researchers are eager to patent their discoveries. But what percentage of patents actually lead to marketable technologies? Diane Fabel of Stony Brook’s Center for Biotechnology has done an analysis that shows, as she explains that “only about 5% of the patents at the USPTO [US Patent and Trademark Office] are ever licensed. Ninety-five percent of them go nowhere.” It’s important to keep in mind that “it’s a very large portfolio of patents at the USPTO. Even a small percentage is a large number, but still it’s only 5%, and only 8.4% of NIH funded projects lead to a patent…I don’t think it would take much to increase those numbers with forethought and infrastructure. You just have to make that the goal.”